Your browser doesn't support javascript.
loading
Identification of Novel, Potent, and Orally Available GCN2 Inhibitors with Type I Half Binding Mode.
Fujimoto, Jun; Kurasawa, Osamu; Takagi, Terufumi; Liu, Xin; Banno, Hiroshi; Kojima, Takuto; Asano, Yasutomi; Nakamura, Akito; Nambu, Tadahiro; Hata, Akito; Ishii, Tsuyoshi; Sameshima, Tomoya; Debori, Yasuyuki; Miyamoto, Maki; Klein, Michael G; Tjhen, Richard; Sang, Bi-Ching; Levin, Irena; Lane, Scott Weston; Snell, Gyorgy P; Li, Ke; Kefala, Georgia; Hoffman, Isaac D; Ding, Steve C; Cary, Douglas R; Mizojiri, Ryo.
Afiliação
  • Fujimoto J; Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.
  • Kurasawa O; Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.
  • Takagi T; Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.
  • Liu X; Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.
  • Banno H; Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.
  • Kojima T; Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.
  • Asano Y; Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.
  • Nakamura A; Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.
  • Nambu T; Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.
  • Hata A; Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.
  • Ishii T; Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.
  • Sameshima T; Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.
  • Debori Y; Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.
  • Miyamoto M; Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.
  • Klein MG; Takeda California, Inc., 10410 Science Center Drive, San Diego, California 92121, United States.
  • Tjhen R; Takeda California, Inc., 10410 Science Center Drive, San Diego, California 92121, United States.
  • Sang BC; Takeda California, Inc., 10410 Science Center Drive, San Diego, California 92121, United States.
  • Levin I; Takeda California, Inc., 10410 Science Center Drive, San Diego, California 92121, United States.
  • Lane SW; Takeda California, Inc., 10410 Science Center Drive, San Diego, California 92121, United States.
  • Snell GP; Takeda California, Inc., 10410 Science Center Drive, San Diego, California 92121, United States.
  • Li K; Takeda California, Inc., 10410 Science Center Drive, San Diego, California 92121, United States.
  • Kefala G; Takeda California, Inc., 10410 Science Center Drive, San Diego, California 92121, United States.
  • Hoffman ID; Takeda California, Inc., 10410 Science Center Drive, San Diego, California 92121, United States.
  • Ding SC; Takeda California, Inc., 10410 Science Center Drive, San Diego, California 92121, United States.
  • Cary DR; Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.
  • Mizojiri R; Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.
ACS Med Chem Lett ; 10(10): 1498-1503, 2019 Oct 10.
Article em En | MEDLINE | ID: mdl-31620240

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies Idioma: En Ano de publicação: 2019 Tipo de documento: Article